MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412479 | Name: CDP 840 (free base)

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CDP 840 (free base) is a selective and potent inhibitor of PDE 4

Chemical Structure

CDP 840 (free base)
CAS#162542-90-7 (free base)

Theoretical Analysis

MedKoo Cat#: 412479

Name: CDP 840 (free base)

CAS#: 162542-90-7 (free base)

Chemical Formula: C25H27NO2

Exact Mass: 373.2042

Molecular Weight: 373.49

Elemental Analysis: C, 80.40; H, 7.29; N, 3.75; O, 8.57

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
162542-90-7 (HCl Salt) ; 190205-74-4 (Free Base)
Synonym
CDP 840; Cdp840; Cdp 840 Cdp-840
IUPAC/Chemical Name
Pyridine, 4-(2-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-phenylethyl)-, (R)-
InChi Key
UTUUPXBCDMQYRR-HSZRJFAPSA-N
InChi Code
InChI=1S/C25H27NO2/c1-27-24-12-11-21(18-25(24)28-22-9-5-6-10-22)23(20-7-3-2-4-8-20)17-19-13-15-26-16-14-19/h2-4,7-8,11-16,18,22-23H,5-6,9-10,17H2,1H3/t23-/m1/s1
SMILES Code
COC1=CC=C([C@@H](C2=CC=CC=C2)CC3=CC=NC=C3)C=C1OC4CCCC4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 373.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Jones TR, McAuliffe M, McFarlane CS, Piechuta H, Macdonald D, Rodger IW. Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma. Can J Physiol Pharmacol. 1998 Feb;76(2):210-7. PMID: 9635162. 2: Li C, Chauret N, Trimble LA, Nicoll-Griffith DA, Silva JM, MacDonald D, Perrier H, Yergey JA, Parton T, Alexander RP, Warrellow GJ. Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimization. Drug Metab Dispos. 2001 Mar;29(3):232-41. PMID: 11181489. 3: Aggarwal VK, Bae I, Lee HY, Richardson J, Williams DT. Sulfur-ylide-mediated synthesis of functionalized and trisubstituted epoxides with high enantioselectivity; application to the synthesis of CDP-840. Angew Chem Int Ed Engl. 2003 Jul 21;42(28):3274-8. doi: 10.1002/anie.200350968. PMID: 12876742. 4: Souness JE, Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal. 1997 May-Jun;9(3-4):227-36. doi: 10.1016/s0898-6568(96)00173-8. PMID: 9218122. 5: Laliberté F, Liu S, Gorseth E, Bobechko B, Bartlett A, Lario P, Gresser MJ, Huang Z. In vitro PKA phosphorylation-mediated human PDE4A4 activation. FEBS Lett. 2002 Feb 13;512(1-3):205-8. doi: 10.1016/s0014-5793(02)02259-7. PMID: 11852080. 6: Pon DJ, Plant M, Tkach J, Boulet L, Muise E, Allen RA, Rodger IW. Characterization of CHO-K1 cells stably expressing PDE-IV enzymes. Whole-cell cAMP determinations vs broken-cell enzymatic assays. Cell Biochem Biophys. 1998;29(1-2):159-78. doi: 10.1007/BF02737834. PMID: 9631244. 7: Zhao Y, Zhang HT, O'Donnell JM. Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram. J Pharmacol Exp Ther. 2003 May;305(2):565-72. doi: 10.1124/jpet.102.47407. Erratum in: J Pharmacol Exp Ther. 2003 Dec;307(3):1243. PMID: 12704225. 8: Guay D, Hamel P, Blouin M, Brideau C, Chan CC, Chauret N, Ducharme Y, Huang Z, Girard M, Jones TR, Laliberté F, Masson P, McAuliffe M, Piechuta H, Silva J, Young RN, Girard Y. Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor. Bioorg Med Chem Lett. 2002 Jun 3;12(11):1457-61. doi: 10.1016/s0960-894x(02)00190-7. PMID: 12031319. 9: Abdollahi M, Chan TS, Subrahmanyam V, O'Brien PJ. Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol Cell Biochem. 2003 Oct;252(1-2):205-11. doi: 10.1023/a:1025568714217. PMID: 14577594. 10: Chauret N, Guay D, Li C, Day S, Silva J, Blouin M, Ducharme Y, Yergey JA, Nicoll-Griffith DA. Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2149-52. doi: 10.1016/s0960-894x(02)00349-9. PMID: 12127525.

View History

CDMG2

CDMG2